

<u>Yale Pulmonary Critical Care and</u> <u>Sleep Medicine Grand Rounds</u>



Presented by Yale School of Medicine, Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine

# Oligometastatic Lung Cancer: A New Paradigm



## Lynn Tanoue, MD

Professor of Medicine Vice Chair for Clinical Affairs, Department of Internal Medicine Director, Lung Cancer Screening Program Yale School of Medicine

### Wednesday, November 4, 2020 @ 3-4 pm EDT

#### Moderator: Jennifer Possick, MD

REMOTE ATTENDANCE ONLY – NO LOCAL AUDIENCE

PC, Mac, Linux, iOS or Android: <u>https://zoom.us/j/94544698749</u> Telephone: Dial: +1 203 432-9666 or (+1 888 788-0099 or +1 877 853-5247 US Toll-free); Meeting ID: 945 4469 8749

CME credit for live event only.

There is no corporate support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

#### ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### TARGET AUDIENCE

Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

#### NEEDS ASSESSMENT

Oligometastatic cancer is a new paradigm in oncology. A subset of cancer patients with metastatic disease may be candidates for local therapies to achieve control of metastatic sites, with improved survival. The international lung cancer staging system recognizes this group of patients with oligometastatic disease among patients with Stage IV lung cancer. For these patients, a treatment approach beyond standard palliative care should be considered.

#### LEARNING OBJECTIVES

At the conclusion of this talk, individuals will:

- 1. Understand the concept of oligometastatic disease
- 2. Distinguish between oligometastatic vs metastatic cancer

3. Review the impact of oligometastatic disease on treatment of Stage IV lung cancer

#### DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for I AMA PRA Category I Credit(s)<sup>TM</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

#### FACULTY DISCLOSURES

Richard Matthay, MD, Course Director – No conflicts of interest

Lynn Tanoue, MD - No conflicts of interest

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past I2 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.